From the Journals

Cortical thinning in adolescence ‘definitively’ tied to subsequent psychosis


 

Definitive findings

Commenting on the findings for an interview, Russell Margolis, MD, clinical director, Johns Hopkins Schizophrenia Center, said that “it’s not so much that the findings are novel but rather that they’re fairly definitive in that this is by far the largest study of its kind looking at this particular question, and that gives it power. The problem with imaging studies has often been inconsistent results from study to study because of small sample size.”

“In order to see these differences in a robust way, you need a large sample size, meaning that for any one individual, this kind of structural imaging is not going to add much to the prediction of whether someone will eventually develop a schizophrenia-like illness,” said Dr. Margolis, professor of psychiatry and behavioral sciences, Johns Hopkins University, Baltimore.

From a clinical standpoint, Dr. Margolis said the findings probably won’t change practice, but they have implications for understanding the neurobiology of psychotic disorders.

“The predominant hypothesis in the field is that early developmental abnormalities are the root cause of schizophrenia and related disorders, and this study is consistent with that, particularly the age-related differences, which are suggestive of neurodevelopmental abnormalities preceding the development of overt symptoms, which many other findings have also suggested,” Dr. Margolis said.

“Abnormalities in cortical thickness could be from a number of different neurobiological processes, and research into those processes are worth investigating,” he added.

The researchers received support from numerous funders, all of which are listed in the original article, along with author disclosures for ENIGMA working group members. Dr. Margolis has disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

The cloudy role of cannabis as a neuropsychiatric treatment
MDedge Family Medicine
Structural racism tied to psychosis risk in Black people
MDedge Family Medicine
Prevalence of psychiatric disorders higher in adult cerebral palsy patients
MDedge Family Medicine
Psychosis, depression tied to neurodegeneration in Parkinson’s
MDedge Family Medicine
APA, AMA, others move to stop insurer from overturning mental health claims ruling
MDedge Family Medicine
FDA fast tracks testing of schizophrenia drug for impaired cognition
MDedge Family Medicine
FDA okays new drug option for schizophrenia, bipolar I disorder
MDedge Family Medicine
Emotional support animals help lick symptoms of depression, anxiety in serious mental illness
MDedge Family Medicine
Once-weekly oral antipsychotic for schizophrenia on the horizon
MDedge Family Medicine
Schizophrenia meds a key contributor to cognitive impairment
MDedge Family Medicine